FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 10/2024”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of October 2024 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 7,381m
- Biotech/Pharma received 60% of the total investment volume (EUR 4,442m) with oncology being the leading indication (44%)
- In October, Nelly (Germany) secured the highest transaction volume with EUR 100m, followed by Purespring Therapeutics (United Kingdom) with EUR 95m and AgomAb (Belgium) with EUR 89m
- General Atlantic (United States) is the most active investor (by deal volume in 2024), followed by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To access the full report, please click here.